Health, Longevity & Biohacking

Otvos says ‘fluffy’ LDL does not offset risk when LDL particle count is high

Name: Otvos says ‘fluffy’ LDL does not offset risk when LDL particle count is high
Uploaded: 2026-08-03T04:19:00+00:00
Description: Asked about patients who argue that large, “buoyant” LDL particles make high LDL particle number less concerning, Otvos rejects the claim. He says analyses show LDL size does not add predictive value once LDL particle number is accounted for, and cites familial hypercholesterolaemia as an example where LDL particles can be large yet risk remains high.

Peter Attia Drive · 402 ‒ NMR blood analysis: how mortality risk and more can be assessed from a single blood sample · August 3, 2026

Peter Attia Drive

402 ‒ NMR blood analysis: how mortality risk and more can be assessed from a single blood sample

""I would say that's uh a facious idea. Um, and and the data that I mentioned supports it completely.""

Asked about patients who argue that large, “buoyant” LDL particles make high LDL particle number less concerning, Otvos rejects the claim. He says analyses show LDL size does not add predictive value once LDL particle number is accounted for, and cites familial hypercholesterolaemia as an example where LDL particles can be large yet risk remains high.

About this episode

Peter Attia interviews Jim Otvos, a physical chemist who developed NMR-based blood analysis that underpins advanced lipoprotein testing (LDL-P/HDL-P). Otvos recounts how a disputed 1980s New England Journal of Medicine cancer claim led his lab to identify reproducible NMR signals from lipoprotein particles, enabling rapid particle quantification and later subclass sizing. He argues that apparent risk from “small, dense” LDL is largely explained by higher LDL particle numbers at a given LDL-cholesterol level, warning against the common “large, fluffy LDL is safe” interpretation.

The discussion then centres on discordance between LDL-C and LDL-P, links to insulin resistance, and how NMR-derived composite scores such as LPIR and the Diabetes Risk Index may help identify metabolic risk earlier than glucose-based criteria. Otvos also describes “glyc”, an NMR-derived inflammation marker tied to glycosylated acute-phase proteins, which he says is more stable than CRP.

A major focus is MVX (metabolic vulnerability index), a composite score (including small HDL-P, glyc, citrate and branched-chain amino acids) that Otvos says strongly predicts all-cause mortality across cohorts, including claims of prediction in a young-adult cohort followed for decades. Finally, he gives an insider account of Liposcience’s acquisition by LabCorp, saying it halted plans to deploy FDA-cleared Vanta NMR analysers broadly and raising concerns about the ageing analyser fleet and long-term continuity of NMR testing.

Key takeaways

Otvos says LDL particle number (LDL-P/ApoB) better reflects LDL-related risk management than LDL-C when the two are discordant.
He argues LDL size adds little once LDL-P is accounted for, challenging the idea that ‘large, fluffy’ LDL is benign.
Otvos describes NMR ‘glyc’ as a composite systemic inflammation marker that is less day-to-day variable than CRP and correlates with IL-6.
LPIR and related NMR metrics are presented as tools for earlier assessment of insulin resistance and future diabetes risk, with Otvos citing unpublished DPP analyses.
MVX is described as a composite NMR-derived score that predicts all-cause mortality in multiple cohorts; Otvos previews work in a young-adult cohort with long follow-up.
He says Liposcience’s 2014 acquisition by LabCorp ended efforts to distribute Vanta NMR analysers widely, and warns the existing analyser fleet may be nearing end of life.
Otvos claims NMR spectra can be processed with machine learning to output an extended lipid panel including ApoB without added analytic cost.

More stories More from Peter Attia Drive